Transcripts Ribomic Inc.

Stocks

Market Closed - Japan Exchange 02:30:00 2026-10-02 EDT			5-day change	1st Jan Change
76.00 ^JPY	-5.00%		0.00%	-2.56%

08-24	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia	CI
08-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI

22-11-11	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	CI
22-08-09	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	CI
22-05-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2022	CI
21-11-09	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022	CI
21-08-06	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022	CI
21-05-25	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022	CI
21-02-11	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2021	CI
20-08-06	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2021	CI
20-05-13	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2021	CI
20-02-06	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
19-11-27	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020	CI
19-08-23	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
17-08-21	Ribomic Inc. Announces Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2018	CI